Pricing and reimbursement: getting onto the Spezialitätenliste
Swissmedic approval lets you sell. Reimbursement is a second, separate procedure at the Federal Office of Public Health, and it decides whether your product has a market. External providers prepare, file and defend the application.
What is the Spezialitätenliste?
The Spezialitätenliste (SL), in French the liste des spécialités (LS) and in Italian the elenco delle specialità (ES), is the list of medicines reimbursed by Swiss compulsory health insurance, with a binding maximum price per pack. It is maintained by the Federal Office of Public Health, not by Swissmedic, and listing is a separate application after authorisation.
For a prescription product the practical rule is simple: not on the SL means the patient pays privately, so volumes stay marginal outside a few self-pay niches. That is why the reimbursement application belongs in the launch plan from the beginning, not after approval.
Two authorities, two decisions
Swissmedic decides whether a medicine may be placed on the market: quality, safety, efficacy. The Federal Office of Public Health decides whether compulsory health insurance pays for it and at what maximum price, on the criteria of effectiveness, appropriateness and economy. The two procedures are independent and use different documents.
How is the Swiss price determined?
The economy criterion is assessed with two instruments: an international price comparison against a defined basket of reference countries, and a therapeutic cross-comparison against the alternatives already listed in Switzerland. The two are combined, each weighted equally in the standard case, and the result caps the ex-factory price.
- International price comparison. The ex-factory prices of the same product in the reference countries, corrected for currency and package differences.
- Therapeutic cross-comparison. The cost of the therapy compared with the listed alternatives for the same indication.
- Innovation consideration. A premium is possible where a therapeutic advance is demonstrated, and it has to be argued with data.
- Limitations. The FOPH can restrict reimbursement to an indication, a patient group, a prescriber group or a duration.
- Periodic review. Listed products are reviewed on a three-year cycle, and the review usually means a price cut.
What external providers do in a reimbursement mandate
External providers build the file, argue it and then defend the price for as long as the product is listed. The first submission decides the price level; the reviews decide how much of it survives.
- Feasibility and price strategy before launch, including the effect of your EU prices on the Swiss comparison.
- Assembly of the SL application: clinical value, comparator selection, price comparison, cross-comparison, cost consequences.
- Filing with the FOPH and handling the questions and the expert commission process.
- Negotiation of limitations, because the wording of a limitation determines real access.
- Publication and price implementation, including wholesaler and article data updates.
- Three-year review defence, plus any generic or biosimilar price effects.
| Factor | Effect | What external providers do about it |
|---|---|---|
| Your prices in reference countries | Cap the comparison | Model it before you set EU prices |
| Choice of comparator therapy | Sets the cross-comparison | Argue the clinically correct comparator |
| Demonstrated therapeutic advance | Possible premium | Build the dossier for it |
| Indication breadth | Volume and limitation wording | Negotiate usable limitations |
| Three-year review | Downward pressure | Prepare evidence ahead of the cycle |
| Generic or biosimilar entry | Price cuts | Plan the life cycle around it |
Orphan drugs and other special situations
Small patient numbers change the reimbursement conversation rather than removing it. Where an international comparison is thin because the product is authorised in few countries, the therapeutic cross-comparison and the clinical argument carry more weight. There are also reimbursement routes for individual cases outside the SL, which matter for products with a small Swiss population but are not a substitute for a listing.
Their orphan drug page summarises the Swiss specifics for rare disease products.
Frequently asked questions
How long does an SL listing take after Swissmedic approval?
The FOPH procedure runs in its own rhythm with fixed meeting cycles of the advisory commission, and the duration depends on how contested the price is. Plan on several months and file as early as the procedure allows, which for many products means before the Swissmedic decision is final.
Can we sell in Switzerland without an SL listing?
Legally yes, once Swissmedic has authorised the product. Commercially it is only viable where patients or hospitals pay directly. For a reimbursed indication, being outside the SL puts you at a structural disadvantage against listed competitors.
Does our EU price affect the Swiss price?
Yes, directly, through the international price comparison. This is the single most underestimated link in Swiss market access: an aggressive discount in a reference country lands in the Swiss calculation. External providers model that before you commit to European prices.
What happens in the three-year review?
The FOPH recalculates the price comparison and the cross-comparison with current data. Where the calculation shows a lower price, the price is reduced. External providers prepare the review with current comparator data and argue the therapeutic value rather than waiting for the letter.
Enquire about Swiss MAH support
Describe your product, dossier status and support needs. Enquiries reach the website operator at info@mahswitzerland.com. Provider qualifications, availability and contracts must be checked separately.
- Independent information portal
- Public Swiss sources, independent explanations, and enquiries about external specialist services.